nlspharma.com (NLSP) - Long-Term Debt to Capital Coefficient
NLS Pharmaceutics AG (NLSP) is developing non-hormonal therapies to treat ADHD and narcolepsy, protecting its market position through unique drug delivery methods. The drug development process is based on the digitalization of clinical data analysis, which eliminates routine tasks. The company's financial status depends on regulatory approvals and stands at 0.00. The asset's market value dynamics are presented below.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_NLSP_-_NLS-Pharmaceutics-AG_-_Long-Term-Debt-to-Capital "NLSP: NLS Pharma Long-Term Debt to Capital 07/04/2022 - 10/31/2025 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for NLS Pharmaceutics Ltd. (NLSP)
Investors should utilize this indicator to stress-test business resilience against borrowing costs. NLS Pharmaceutics AG (NLSP) is developing unique cognitive drugs, aiming for premium pricing power within the ADHD niche. Analyzing the long-term debt-to-equity ratio allows for an assessment of the share of long-term loans within the financing structure. An increase in this metric may indicate aggressive R&D scaling, while a decrease reflects deleveraging and the company's financial autonomy.